New hope for Hard-to-Treat lymphoma: drug cocktail shows promise
NCT ID NCT07184788
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a combination of three drugs (glofitamab, polatuzumab vedotin, and chemotherapy) in 80 adults with aggressive B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this cocktail can shrink tumors and improve survival. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glofitamab, Polatuzumab vedotin, Gemcitabine, Oxaliplatin
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with aggressive B-cell lymphoma that has not responded to prior therapy.
- What could go wrong
- This is an early-phase trial with only 80 participants, so results may not apply to all patients. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.